A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2018
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 12 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.